Metabolic and Non-Cognitive Manifestations of Alzheimers Disease: The Hypothalamus as Both Culprit and Target of Pathology Review uri icon


MeSH Major

  • Alzheimer Disease
  • Biomarkers
  • Cognition
  • Neuroendocrine Cells


  • Alzheimer's disease (AD) is increasingly recognized as a complex neurodegenerative disease beginning decades prior to the cognitive decline. While cognitive deficits remain the cardinal manifestation of AD, metabolic and non-cognitive abnormalities, such as alterations in body weight and neuroendocrine functions, are also present, often preceding the cognitive decline. Furthermore, hypothalamic dysfunction can also be a driver of AD pathology. Here we offer a brief appraisal of hypothalamic dysfunction in AD and provide insight into an underappreciated dual role of the hypothalamus as both a culprit and target of AD pathology, as well as into new opportunities for therapeutic interventions and biomarker development.

publication date

  • January 2015



  • Review



  • eng

PubMed Central ID

  • PMC4654127

Digital Object Identifier (DOI)

  • 10.1016/j.cmet.2015.08.016

PubMed ID

  • 26365177

Additional Document Info

start page

  • 761

end page

  • 76


  • 22


  • 5